Kevin M Kalinsky MD MS

Oncology•Atlanta, GA

Hematologic Oncology

Associate Professor of Medicine, Winship Cancer Institute at Emory University

Join to View Full Profile

1365 Clifton Rd NEAtlanta, GA 30322
Phone+1 404-778-1900
Fax+1 212-305-0178

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2009
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Tufts Medical CenterResidency, Internal Medicine, 2002 - 2005
Medical University of South CarolinaClass of 2002

Certifications & Licensure

GA State Medical License 2020 - 2025
NY State Medical License 2008 - 2025
MA State Medical License 2006 - 2008
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2009 Jul 02
Completed
Phase 2
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer Start of enrollment: 2009 Sep 01
Completed
Phase 1
Adjuvant Valproate for High Grade Sarcomas Start of enrollment: 2009 Oct 01
Terminated
Phase 1
Electro-acupuncture for the Prevention of Taxane Induced Myalgias and Neuropathy Start of enrollment: 2010 Dec 01
Completed
Not Applicable
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Start of enrollment: 2011 Apr 01
Terminated
Phase 2
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Start of enrollment: 2012 Oct 01
Completed
Phase 2
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer Start of enrollment: 2013 Oct 01
Completed
Early Phase 1
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer Start of enrollment: 2014 Jun 01
Completed
Phase 1, Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
ACTIVE_NOT_RECRUITING
PHASE3
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
COMPLETED
PHASE2
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer Start of enrollment: 2016 Mar 01
Completed
Phase 1
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) Start of enrollment: 2016 May 31
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

5 citations
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.
Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L Graff, Kyong Hwa Park
Journal of Clinical Oncology. 2025-03-20
1 citations
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
Lajos Pusztai, Jess R Hoag, Kathy S Albain, William E Barlow, Salomon M Stemmer
Journal of Clinical Oncology. 2025-03-10
Comprehensive Molecular and Genomic Analysis of NCI-MATCH Subprotocol Y: Capivasertib in Patients With an-Mutated Tumor.
Carolyn K McCourt, Jacob Gross, Kevin Kalinsky, Ping Guan, Lisa M McShane
JCO Precision Oncology. 2025-03-01

Journal Articles

Effect of Capivasertib in Patients with an AKT1 E17K-Mutated Tumor
Kevin Kalinsky, Edith P Mitchell, Barbara A Conley, Lyndsay N Harris, Carlos L Arteaga, Alice P Chen, Keith T Flaherty, JAMA Oncology

Lectures

Enhancing Checkpoint Inhibitors in Triple-Negative Breast Cancer. Breast Cancer Immunotherapy: Can We Crack the Code?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

New Chief Surgical Officer at Winship Cancer Institute of Emory University – Tari King, MDMarch 10th, 2025
The Evolving Landscape of CDK4/6i Therapy in Metastatic Breast Cancer: Experts Discuss Key Findings and Future DirectionsMarch 9th, 2025
RSClin Tool N+ Enhances Breast Cancer Risk EstimatesJanuary 23rd, 2025
Join now to see all